742131
Last Update Posted: 2017-07-31
Recruiting has ended
All Genders accepted | 18 Years + |
40 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
Eligibility
Relevant conditions:
Solid Tumours
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov